The data on the prospects for the Chinese economy is mixed, says MoneyShow's Jim Jubak, while the GDP numbers are encouraging, the corporate numbers are not yet.
We are seeing a very, very mixed picture on the Chinese economy, that the official numbers, which sort of focus on GDP growth, look like they are pretty strong. It looks like we are going to see better growth for the last, oh, for September, October, November, December, and then into 2014 than we have seen before. That is at least what we are getting out of official numbers like the Purchasing Managers' Index, which came in slightly above expectations for September. On the other hand, if you look at, not the GDP numbers, but the corporate numbers, they are looking kind of grim.
What those numbers are reporting, whether it is from an organization such as Forensic Asia, which looks at corporate accounting and stocks in the Chinese market, or whether it is from something called China Beige Book, which is an attempt to pull together economic numbers for China the same way that the Fed does for the United States, but it is a private company, what they are saying is that while GDP may be growing, because you have over capacity, because you have falling prices, what you are seeing is not much in the way of revenue growth at a lot of companies, they are competing for too little market among too many companies, and you are seeing profits fall.
Top India Stocks To Own Right Now: PTC Therapeutics Inc (PTCT)
PTC Therapeutics, Inc., incorporated on March 31, 1998 , is a biopharmaceutical company focused on the discovery and development of orally administered, small-molecule drugs that target post-transcriptional control processes. The Company�� lead product candidate includes ataluren, which is used for the treatment of patients with genetic disorders that arise from a type of genetic mutation known as a nonsense mutation. Ataluren is in late stage clinical development for the treatment of Duchenne muscular dystrophy caused by nonsense mutations (nmDMD) and cystic fibrosis caused by nonsense mutations (nmCF).
Ataluren is orally administered small-molecule compound that targets nonsense mutations. The Company is engaged in the development of ataluren for the treatment of genetic disorders in, which a nonsense mutation is the cause of the disease. Genetic tests are available for many genetic disorders, including Duchenne muscular dystrophy and cystic fibrosis, to determine if the underlying cause is a nonsense mutation. The EMA has designated ataluren as an orphan medicinal product for the treatment of nmDMD and nmCF. During the year ended December 31, 2012, the Phase III clinical trial completed. The Company�� Ataluren clinical trials in patients with nonsense mutation genetic disorders include Ataluren for nmDMD: Phase 2b clinical trial complete; Confirmatory Phase III clinical trial initiated, and Ataluren for nmCF: Phase III trial completed.
Advisors' Opinion:- [By WWW.DAILYFINANCE.COM] Records fell on Wall Street Friday as another solid report on housing lifted the market for the second day in a row. There's a three-day weekend coming up -- something that often prompts investor caution -- but the gains were broad-based even though volume was fairly light. The VIX, which measures volatility, fell to its lowest level this year. The Dow Jones industrial average (^DJI) gained 63 points, the Nasdaq composite (^IXIC) rose 31, and the Standard & Poor's 500 index (^GPSC) added 8, topping the record high set last week. The Dow Transportation average also raced to an all-time high, lifted by airline stocks. United (UAL) soared more than 4 percent; Delta (DAL) gained more than 1 percent and Southwest (LUV) gained 2 percent. Southwest is at an all-time high, up 79 percent from a year ago. New home sales bounced back with a better than expected 6.4 percent increase last month. Lennar (LEN) and D.R. Horton (DHI) both rose 4 percent. Pulte (PHM), Beazer (BZH) and Hovnanian (HOV) also solid posted gains. Earnings continue to drive retail stocks. Gap (GPS) edged higher even though net fell. Foot Locker (FL) gained 1½ percent after topping expectations. GameStop (GME) rose 4 percent. Its net rose, helped by the rollout last year of new Xbox and PlayStation consoles. Zumiez (ZUMZ) rose 5½ percent on an earnings beat. But Aeropostale (ARO) tumbled 24 percent. Its loss widened and sales declined. The retailer continues to struggle with teen fashion trends. Also on the earnings front, TiVo (TIVO) rose 2 percent as it swung to a profit from a year ago loss. It also reported an increase in the number of subscribers. Hewlett-Packard (HPQ) rose 6 percent on news the company plans to eliminate up to 16,000 additional workers in an effort to cut costs. And several stocks extended big moves from yesterday. Best Buy (BBY) rose more than 3 percent for the second straight day after earnings beat expectations. Isis Pharmaceuticals (ISIS) jumped
- [By John Kell]
PTC Therapeutics Inc.(PTCT) said the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative opinion on the biopharmaceutical company’s marketing authorization application for its muscular dystrophy treatment. Shares slumped 21% to $20.60 in premarket trading.
Best Healthcare Technology Companies To Invest In 2014: ProShares UltraShort Russell2000 (TWM)
ProShares UltraShort Russell2000 (the Fund) seeks daily investment results that correspond to twice (200%) the inverse (opposite) of the daily performance of the Russell 2000 Index (the Index). The Fund intends to invest at least 80% of its net assets, including any borrowings for investment purposes, to investments that, in combination, have economic characteristics that are inverse to those of the Index. The Fund also intends to invest assets not invested in financial instruments, in debt instruments and/or money market instruments. The Fund intends to concentrate its investments in a particular industry or group of industries to approximately the same extent as the Index is so concentrated. ProShare Advisors LLC serves as the investment advisor to the Fund. Advisors' Opinion:- [By Richard Rhodes]
We remain short, via a position, the Russell 200 2X Short (TWM) as well as short positions in Tesla (TSLA) and Chipolte (CMG).
Subscribe to The Rhodes Report here��/p>
Best Healthcare Technology Companies To Invest In 2014: Heidrick & Struggles International Inc (HSII)
Heidrick & Struggles International, Inc. (Heidrick & Struggles) is an advisory firm providing executive search and leadership consulting services. As of December 31, 2011, the Company provided its services to a range of clients through the expertise of 347 consultants located in various cities around the world. The Company�� service offerings include executive search, leadership consulting and client base. The Company helps its clients build leadership teams by facilitating the recruitment, management and deployment of senior executives. In addition to executive search, it provides a range of leadership consulting services to clients. These services include succession planning, executive assessment, talent retention management, executive development, transition consulting for newly appointed executives, and mergers and acquisitions human capital integration consulting. In November 2013, Heidrick & Struggles International, Inc announced the acquisition of Scambler MacGregor.
The Company�� clients includes clients include Fortune 1000 companies, non-United States companies, middle market and emerging growth companies, governmental, higher education and not-for-profit organizations and other private and public entities. Heidrick & Struggles provides senior-level executive search and leadership consulting services to its clients worldwide through a network of more than 69 offices in 40 countries. The locations are staffed with consultants, research associates, administrative assistants and other support staff. Administrative functions are centralized where possible, although certain support and research functions are situated regionally because of variations in local requirements.
The Company�� worldwide network includes affiliate relationships in Finland, South Africa, Turkey and Portugal. It has no financial investment in these affiliates but receive licensing fees from them for the use of its name and its databases. Licensing fees are less than 1% of its net revenue. As ! of December 31, 2011, the Company had 160 consultants in its Americas segment, which included New York, Chicago and Atlanta. As of December 31, 2011, the Company had 104 consultants in its European segment, which included the United Kingdom, Germany and France. As of December 31, 2011, the Company had 83 consultants in itsAsia Pacific segment, which included China (including Hong Kong), Australia and Singapore. The Company�� executive search business operates in six broad industry groups: Financial Services, Industrial, Consumer Markets, Global Technology and Services, Life Sciences, and Education and Social Enterprise.
Its executive search consultants also specialize in searches for specific C-level functional positions, which are roles that generally report directly to the chief executive officer. These include chief financial officers, chief information officers, chief legal officers, chief marketing officers and chief human resources officers. The Company�� Global Functional Practices include Chief Executive Officer and Board of Directors; Chief Human Resources Officers; Financial Officers; Information Officers; Interim Executives; Legal, Risk, Compliance & Government Affairs; Marketing, Sales & Strategy Officers; Multicultural & Digital Marketing; Sales Officers; Research & Development; and Supply Chain & Transportation.
The Company competes with Egon Zehnder International, Korn/Ferry International, Russell Reynolds Associates, Inc. and Spencer Stuart & Associates.
Advisors' Opinion:- [By Anders Bylund]
And if you thought this crack team would look only at internal promotion candidates, headhunter firm Heidrick & Struggles (NASDAQ: HSII ) is there to vet the field of outsider candidates. It's a high-profile contract for Heidrick, but the stock fell 0.7% today anyhow. The lack of popping champagne corks in the company's Chicago headquarters is an indication of just how tough this recruitment drive will be.
- [By Rich Smith]
Chicago-based Heidrick & Struggles (NASDAQ: HSII ) needs a new CEO.
For weeks, rumors have swirled that Heidrick was on the block for possible sale to a new owner. Those rumors were squashed Monday, however, when the executive-search firm simultaneously announced that (a) it has decided to pursue a "stand-alone strategy," and (b) that Chief Executive Officer L. Kevin Kelly is leaving the company. (The company also had some good news -- revenues for the fiscal second quarter look to be close to the high point of its previously announced $110 million-to-$120 million range.)
- [By GuruFocus]
Heidrick & Struggles International Inc. (HSII): Interim CEO Jory J. Marino Bought 9,917 Shares
Interim CEO of Heidrick & Struggles International Inc. (HSII) Jory J. Marino bought 9,917 shares on 08/23/2013 at an average price of $15.03. Heidrick & Struggles International Inc. was formed as a Delaware corporation in 1999. Heidrick & Struggles International Inc. has a market cap of $272.497 million; its shares were traded at around $15.03 with a P/E ratio of 61.73 and P/S ratio of 0.58. The dividend yield of Heidrick & Struggles International Inc. stocks is 3.46%.
Best Healthcare Technology Companies To Invest In 2014: iShares 20+ Year Treasury Bond ETF (TLT)
iShares Lehman 20+ Year Treasury Bond Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the long-term sector of the United States Treasury market as defined by the Lehman Brothers 20+ Year U.S. Treasury Index (the Index). The Index includes all publicly issued, the United States Treasury securities that have a remaining maturity greater than 20 years, are non-convertible, are denominated in United States dollars, are rated investment grade (Baa3 or better) by Moody�� Investors Service, are fixed rate, and have more than $150 million par outstanding. Excluded from the Index are certain special issues, such as flower bonds, targeted investor notes, state and local government series bonds, and coupon issues that have been stripped from assets that are already included in the Index.
The Index is a market capitalization-weighted index. The Fund invests in a representative sample of the securities in the Index, which has a similar investment profile as the Index. The Fund�� investment advisor is Barclays Global Fund Advisor.
Advisors' Opinion:- [By Tom Aspray]
The bond market, as represented by the iShares 20+ Year Treasury Bond ETF (TLT) is still up just over 5% as the yield on the 10-Year T-Note is still locked in it's trading range. The generally bullish job report last Friday should allow the Fed to stay on its tapering course for the near future.
Best Healthcare Technology Companies To Invest In 2014: BBVA Banco Frances S.A. (BFR)
BBVA Banco Franc茅s S.A., together with its subsidiaries, provides various financial services to corporations, medium and small companies, and individual customers in the Republic of Argentina. The company offers checking and savings accounts, time deposits, and investment accounts. It also provides short and long-term loans to companies, overdraft lines of credit, discounted instruments, loans to financial institutions and the governmental sector, collateral loans, and real estate mortgage, as well as consumer loans comprising credit card loans and other consumer loans. In addition, the company offers home and personal accident insurance; payroll services; asset management services; and insurance advisory services to customers in the areas of coverage of risks related to life, personal accidents and home insurance, and automated teller machine (ATM) robbery insurance. Further, it provides foreign trade services, including letters of credit, collections, bank drafts, fund transfers, and foreign currency transactions; and electronic banking, ATM, self-service terminals, Internet and mobile banking, call center, and trust services. Additionally, the company engages in capital market and securities activities, principally underwriting and placement of corporate bonds, commercial paper, and equity securities; corporate advisory; and securities brokerage. As of December 31, 2011, it operated 268 branches comprising 240 retail branches, 28 branches specialized in small and medium enterprises segment, 13 in-company branches, 7 corporate banking units, and 3 points of sale, as well as 654 ATM�s and 695 quick deposit boxes. The company was formerly known as Banco Frances del Rio de la Plata S.A. and changed its name to BBVA Banco Franc茅s S.A. in October 2000. The company was founded in 1886 and is based in Buenos Aires, the Republic of Argentina. BBVA Banco Franc茅s SA operates as a subsidiary of Banco Bilbao Vizcaya Argentaria, S.A.
Advisors' Opinion:- [By Federico Zaldua]
Banco Frances (BFR), 75% controlled by Banco Bilbao Viscaya Argentaria, is among the biggest banks in Argentina. The bank has the smallest exposure to Argentina's public debt out of the three banks analyzed in the article and presents the lowest pace of growth. That said, its one of the healthiest banks in the country given that it has the lowest NPL ratio and the highest reserve ratio to absorb potential losses. The bank also trades cheaply at 3.5 times P/E and 85% its book value. Being more expensive (although still very cheap relative to the sector's average) and with the lowest liquidity among this group of three, I would exclude Banco Frances from my Argentinean bank portfolio.
Best Healthcare Technology Companies To Invest In 2014: Pendrell Corp (PCO)
Pendrell Corporation (Pendrell), formerly ICO Global Communications (Holdings) Limited, incorporated on March 17, 2000, is a fully-integrated intellectual property (IP) investment and advisory company. The Company develops and implements strategies to create, acquire, commercialize and license IP. The Company provides IP valuation services, analysis and strategic advice through Pendrell�� wholly owned subsidiary, Pendrell Technologies LLC (PTL) and its wholly owned subsidiary, Ovidian Group LLC (Ovidian Group). It also assists its clients with a rangeof IP services, including IP valuation and investment analysis, IP landscape analysis, IP divestitures and IP risk mitigation strategies. On June 17, 2011, the Company acquired Ovidian Group. On October 31, 2011, the Company�� subsidiary, Pendrell Technologies LLC, acquired 90.1% interest in ContentGuard Holdings, Inc. In November 2011, Technicolor SA sold its 25.7% interest in ContentGuard to Pendrell Technologies LLC, a wholly owned subsidiary of Pendrell Corporation. During the year ended December 31, 2011, the Company completed the divestiture of its satellite communications assets. Effective February 25, 2013, the Company acquired 68% interest in Provitro Biosciences LLC.
The Company competes with Acacia Research Corporation, Coller IP Management, Intellectual Ventures, Mosaid, Rovi, RPX, Wi-Lan, Boston Consulting Group, Bain & Company and Red Chalk Group.
Advisors' Opinion:- [By Roberto Pedone]
Pendrell (PCO) is a fully integrated intellectual property investment and advisory firm. This stock closed up 2.3% to $2.18 in Tuesday's trading session.
Tuesday's Range: $2.08-$2.22
52-Week Range: $1.04-$2.71
Tuesday's Volume: 263,000
Three-Month Average Volume: 457,962From a technical perspective, PCO bounced higher here back above its 50-day moving average of $2.16 with lighter-than-average volume. This move is quickly pushing shares of PCO within range of triggering a near-term breakout trade. That trade will hit if PCO manages to take out some near-term overhead resistance at $2.22 with high volume.
Traders should now look for long-biased trades in PCO as long as it's trending above Tuesday's low of $2.08 or above $2 and then once it sustains a move or close above $2.22 with volume that hits near or above 457,962 shares. If that breakout triggers soon, then PCO will set up to re-test or possibly take out its next major overhead resistance levels at $2.50 to its 52-week high at $2.71.
No comments:
Post a Comment